In the BioHarmony Drug Report Database

"Preview" Icon

Entrectinib

Rozlytrek (entrectinib) is a small molecule pharmaceutical. Entrectinib was first approved as Rozlytrek on 2019-08-15. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat neoplasms and non-small-cell lung carcinoma. Rozlytrek’s patents are valid until 2038-07-18 (FDA).

 

Trade Name

 

Rozlytrek
 

Common Name

 

entrectinib
 

ChEMBL ID

 

CHEMBL1983268
 

Indication

 

neoplasms, non-small-cell lung carcinoma
 

Drug Class

 

Tyrosine kinase inhibitors: tropomyosin receptor kinase (TRK) inhibitors

Image (chem structure or protein)

Entrectinib structure rendering